In both pharmacovigilance databases, ERAM values suggest GLP-1 analogues may exert a clinical meaningful protective effect, as demonstrated by significant reductions of depression-like symptom frequencies in patients with depression and diabetes [point estimates: 0.480 (0.398–0.569) in FAERS and 0.515 (0.403–0.639), in VigiBase]. This evidence concerns the gene GLP1R and diabetes mellitus.